HC Wainwright Has Bearish Forecast for Kamada Q2 Earnings

Kamada Ltd. (NASDAQ:KMDA) – HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for Kamada in a note issued to investors on Thursday, May 14th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $0.11 per share for the quarter, down from their prior forecast of $0.15. The consensus estimate for Kamada’s current full-year earnings is $0.51 per share. HC Wainwright also issued estimates for Kamada’s Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.10 EPS and FY2026 earnings at $0.41 EPS.

KMDA has been the topic of a number of other research reports. Wall Street Zen lowered Kamada from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Stifel Nicolaus set a $11.00 price objective on Kamada in a research report on Wednesday, March 11th. Weiss Ratings raised Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. Finally, Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Thursday, March 12th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $12.00.

Kamada Stock Up 1.6%

Shares of NASDAQ KMDA opened at $7.83 on Tuesday. The firm has a market cap of $450.30 million, a price-to-earnings ratio of 22.37, a PEG ratio of 0.60 and a beta of 0.86. Kamada has a 52-week low of $6.50 and a 52-week high of $9.35. The business’s 50 day moving average is $8.37 and its two-hundred day moving average is $7.90.

Kamada (NASDAQ:KMDA) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). The firm had revenue of $45.24 million during the quarter, compared to analysts’ expectations of $46.72 million. Kamada had a net margin of 11.21% and a return on equity of 7.73%.

Kamada Dividend Announcement

The business also recently disclosed an annual dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a $0.25 dividend. This represents a yield of 305.0%. The ex-dividend date was Monday, March 23rd. Kamada’s dividend payout ratio is currently 54.29%.

Institutional Investors Weigh In On Kamada

Institutional investors and hedge funds have recently made changes to their positions in the business. Essex Investment Management Co. LLC raised its holdings in Kamada by 22.4% during the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock worth $2,751,000 after purchasing an additional 72,602 shares in the last quarter. Huntleigh Advisors Inc. raised its holdings in Kamada by 4.3% during the third quarter. Huntleigh Advisors Inc. now owns 141,562 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 5,786 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Kamada by 9.2% during the fourth quarter. NewEdge Advisors LLC now owns 57,538 shares of the biotechnology company’s stock worth $406,000 after purchasing an additional 4,870 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Kamada by 43.6% during the third quarter. JPMorgan Chase & Co. now owns 40,984 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 12,442 shares in the last quarter. Finally, Man Group plc raised its holdings in Kamada by 19.9% during the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 5,684 shares in the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.